The Cancer Epigenetics Society is happy to announce the appointment of Dr. Ayalew Tefferi to the Editorial Board of Clinical Cancer Epigenetics.
Dr. Tefferi is Professor of Hematology and of Internal Medicine at the Mayo Clinic (Rochester, MN, USA). He also serves as a Board Review Course Faculty at MD Anderson Cancer Center, George Washington University, and Harvard University, and has given more than 700 invited lectures.
Join the Society today as a Professional or Affiliate Member by clicking on the Membership button!
Dr. Tefferi is one of the world’s foremost researchers and clinicians in myeloid disorders including acute myeloid leukemia, chronic myeloid leukemia, chronic neutrophilic leukemia, hypereosinophilic syndrome, mast cell disease, myelodysplastic syndrome, myelofibrosis with myeloid metaplasia, polycythemia vera, systemic mastocytosis, and thrombocythemia. He served on the World Health Organization (WHO) committee in charge of the classification of myeloid neoplasms, and is one of the most prolific authors in the history of science, having published more than 1,000 articles, book chapters, and books.
For his work on myeloproliferative neoplasms, particularly for defining the pathogenesis, prognosis, and treatment of theses malignancies (e.g. his work laid the foundations to the use of JAK inhibitors in patients), Dr. Tefferi received numerous awards, including the Emil J. Freireich Medal and the Henry M. Stratton Medal for Clinical/Translational Science.
In addition to Clinical Cancer Epigenetics, Dr. Tefferi is also Editor of the American Journal of Hematology, Blood, Leukemia, and Journal of Clinical Oncology.
The Cancer Epigenetics Society looks forward to working with Dr. Ayalew Tefferi in establishing the highest standards for papers published on myeloproliferative cancers in the Clinical Cancer Epigenetics journal series (Cancer Epigenetics Society news, September 3, 2017).